Research programme: dendritic cell targeted vaccines - Lipotek

Drug Profile

Research programme: dendritic cell targeted vaccines - Lipotek

Alternative Names: Antigen-encoded DNA vaccines - Lipotek; Lipokel; Lipovax-Fg115-cancer; Lipovax-Fg115-malaria; Lipovax-Fg115-TB; Lipovax-FliC-TB; Lipovaxin; Lipovaxin-TB; R4 - Lipotek

Latest Information Update: 19 Jul 2016

Price : $50

At a glance

  • Originator Lipotek
  • Class Bacterial vaccines; Cancer vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Tuberculosis
  • Research Cancer; Malaria

Most Recent Events

  • 19 Jul 2016 Early research in Malaria in Australia (Parenteral)
  • 19 Jul 2016 Early research in Cancer in Australia (Parenteral)
  • 19 Jul 2016 Preclinical development in Tuberculosis is ongoing in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top